ArticleThe Journal of infectious diseases2019
Differences in the Epstein-Barr Virus gp350 IgA Antibody Response Are Associated With Increased Risk for Coinfection With a Second Strain of Epstein-Barr Virus.
Article in The Journal of infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Equity in protection: bridging global data gaps for an EBV vaccine-a systematic review and meta-analysis.BMJ global health · 2025Pooled it
- Estimating the global burden of Epstein-Barr virus-related cancers.Journal of cancer research and clinical oncology · 2022Pooled it
- Epstein-Barr virus type 2 infection is associated with higher viral loads in pediatric tonsils from western Kenya.Microbiology spectrum · 2025Article
- Epstein-Barr virus BALF0/1 subverts the Caveolin and ERAD pathways to target B cell receptor complexes for degradation.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Detection of EBV DNA in clinically ill patients from 2013 to 2023 in Beijing, China.Frontiers in microbiology · 2025Article
- Epstein-Barr virus (EBV) antibody changes over time in a general population cohort in rural Uganda, 1992-2008.Infectious agents and cancer · 2023Article
- Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice.Nature communications · 2023Article
- Epstein‑Barr virus as a promoter of tumorigenesis in the tumor microenvironment of breast cancer (Review).International journal of molecular medicine · 2023Review
- Review
- Simultaneous occurrence of Epstein-Barr virus (EBV) in periodontal pockets and in oral squamous cell carcinoma: a cross-sectional study.Clinical oral investigations · 2022Article
- Observational
- Maternal Epstein-Barr Virus-Specific Antibodies and Risk of Infection in Ugandan Infants.The Journal of infectious diseases · 2021Article
- Maternal HIV Infection as a Risk Factor for Primary Epstein-Barr Virus Infection in Kenyan Infants.Frontiers in oncology · 2021Article
- Neutralizing Antibodies Protect against Oral Transmission of Lymphocryptovirus.Cell reports. Medicine · 2020Article
- Epstein-Barr Virus and Systemic Autoimmune Diseases.Frontiers in immunology · 2020Review
- A reliable Epstein-Barr Virus classification based on phylogenomic and population analyses.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 3 countries.
Funding
Abstract
backgroundThe Epstein-Barr virus (EBV) viral glycoprotein gp350 has been proposed as a candidate antigen for an EBV vaccine. However, the proposed formulations of these vaccines have not taken into account the presence of 2 unique EBV strains (EBV-1 and EBV-2) present in areas of high incidence of the EBV-associated cancer, Burkitt lymphoma.
methodsIn this study, we analyze the kinetics of EBV-1 and EBV-2 infection in an asymptomatic infant cohort from Kisumu, Kenya. We also analyzed the kinetics of the antibody response against 5 EBV antigens, gp350 (IgG and IgA), VCA (IgG), EBNA-1 (IgG), EAd (IgG), and Zta (IgG).
resultsWe observed a high frequency of coinfection with both EBV types over time, with the only observable defect in the antibody response in infants coinfected being a significantly lower level of anti-gp350 IgA at peak response. Gp350 IgA levels were also significantly lower in coinfected infants 2.5 months postinfection and at the time of coinfection.
conclusionsThese results suggest that anti-gp350 IgA antibodies may be important for sterilizing immunity against secondary infection. These findings have implications for the development of an efficacious EBV vaccine to prevent both EBV-1 and EBV-2 infection in a population at high risk for Burkitt lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.